HTLV-1 Associated Myelopathy (HAM) / Tropical Spastic Paraparesis (TSP)
Introduction
Htlv 1 Associated Myelopathy (Ham) Tropical Spastic Paraparesis (Tsp) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
HTLV-1 Associated Myelopathy (HAM), also known as Tropical Spastic Paraparesis (TSP), is a rare chronic progressive myelopathy caused by infection with the human T-lymphotropic virus type 1 (HTLV-1). This disorder is characterized by chronic inflammation of the spinal cord leading to progressive motor dysfunction, primarily affecting the lower limbs.[@expanding] [@acanthamoeba]
Overview
HAM/TSP is the most common neurological complication of HTLV-1 infection.[@acanthamoeba] The disease typically presents in adulthood, with progressive spastic weakness in the lower extremities, bladder dysfunction, and sensory disturbances. The pathophysiology involves immune-mediated damage to the spinal cord, particularly affecting the lateral and posterior columns.[@htlv]
Key features include: [@epidemiology]
- Progressive course: Symptoms worsen over months to years
- Motor impairment: Spastic paraparesis affecting gait and balance
- Autonomic dysfunction: Urinary urgency, incontinence, and constipation
- No cure: Treatment focuses on symptom management and immunotherapy
Epidemiology
...HTLV-1 Associated Myelopathy (HAM) / Tropical Spastic Paraparesis (TSP)
Introduction
Htlv 1 Associated Myelopathy (Ham) Tropical Spastic Paraparesis (Tsp) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
HTLV-1 Associated Myelopathy (HAM), also known as Tropical Spastic Paraparesis (TSP), is a rare chronic progressive myelopathy caused by infection with the human T-lymphotropic virus type 1 (HTLV-1). This disorder is characterized by chronic inflammation of the spinal cord leading to progressive motor dysfunction, primarily affecting the lower limbs.[@expanding] [@acanthamoeba]
Overview
HAM/TSP is the most common neurological complication of HTLV-1 infection.[@acanthamoeba] The disease typically presents in adulthood, with progressive spastic weakness in the lower extremities, bladder dysfunction, and sensory disturbances. The pathophysiology involves immune-mediated damage to the spinal cord, particularly affecting the lateral and posterior columns.[@htlv]
Key features include: [@epidemiology]
- Progressive course: Symptoms worsen over months to years
- Motor impairment: Spastic paraparesis affecting gait and balance
- Autonomic dysfunction: Urinary urgency, incontinence, and constipation
- No cure: Treatment focuses on symptom management and immunotherapy
Epidemiology
HTLV-1 is endemic in several regions worldwide, including: [@assessment2023]
- Japan (particularly the southwestern islands of Kyushu and Okinawa)[@acanthamoeba]
- Caribbean islands (Jamaica, Haiti, Trinidad)
- Parts of Africa (particularly West Africa)
- South America (Colombia, Brazil)
- Melanesia (Papua New Guinea, Fiji)
The lifetime risk of developing HAM/TSP among HTLV-1 carriers is approximately 0.5-4%, with a higher risk in women and those who acquire infection through breastfeeding in infancy.[@acanthamoeba] The disease typically develops 30-50 years after initial HTLV-1 infection.[^7] [^6]
Pathophysiology
Viral Mechanism
HTLV-1 is a retrovirus that primarily infects CD4+ T lymphocytes. The virus establishes a lifelong infection through integration of its proviral DNA into the host genome. In HAM/TSP, the immune system's response to HTLV-1 antigens triggers chronic neuroinflammation.[@htlv] [^7]
The pathogenesis involves: [^8]
CD8+ cytotoxic T-cell expansion - These cells target HTLV-1-infected cells, releasing inflammatory cytokines[@htlv]
B-cell activation - Production of antibodies against viral and neural antigens
Cytokine dysregulation - Elevated levels of TNF-α, IL-1β, and IFN-γ in cerebrospinal fluid[@epidemiology]
Blood-spinal cord barrier disruption - Allows immune cell infiltration into the spinal cordNeuropathology
- Inflammatory lesions in the lateral and posterior columns of the spinal cord[@assessment2023]
- Loss of myelin (demyelination) and axonal degeneration
- Perivascular lymphocytic infiltrates
- Microglial activation throughout the spinal cord
Clinical Features
Motor Symptoms
- Progressive spastic paraparesis - stiffness and weakness in both legs
- Gait disturbance - difficulty walking, frequent tripping
- Lower extremity spasticity - muscle rigidity, clonus
- Urinary urgency and incontinence - bladder dysfunction
- Constipation - bowel dysfunction
Sensory Symptoms
- Lower back pain - often chronic
- Paresthesias - tingling, numbness in legs
- Impaired vibration sense - particularly in ankles
Other Neurological Features
- Mild cognitive impairment in some cases
- Cerebellar signs (ataxia, tremor) in rare cases
- Peripheral neuropathy in approximately 10% of patients
Diagnosis
Clinical Criteria
Diagnosis is based on the WHO diagnostic criteria:
Chronic progressive spastic paraparesis
HTLV-1 antibodies in serum and cerebrospinal fluid (CSF)
Exclusion of other causes of myelopathy[^8]Laboratory Findings
- Serology: HTLV-1 antibodies positive in serum (ELISA confirmed by Western blot)
- CSF analysis: Mild lymphocytic pleocytosis, elevated protein, HTLV-1 antibodies present
- MRI: May show spinal cord atrophy, particularly in the thoracic region, and white matter lesions[@assessment2023]
Differential Diagnosis
- [Multiple Sclerosis (MS)](/diseases/multiple-sclerosis)
- [Primary Lateral Sclerosis (PLS)](/diseases/primary-lateral-sclerosis)
- [Hereditary Spastic Paraplegia (HSP)](/diseases/hereditary-spastic-paraplegia)
- Vitamin B12 deficiency
- Syphilitic myelopathy
- [Amyotrophic Lateral Sclerosis (ALS)](/therapeutics/amyotrophic-lateral-sclerosis-als-treatment)
Treatment
Disease-Modifying Therapies
No definitive disease-modifying treatment exists. Therapeutic approaches include:
Immunomodulatory therapies:
- Corticosteroids (prednisone): May provide temporary improvement in some patients
- Interferon-alpha: Has shown modest benefit in clinical trials
- Methotrexate: Used in some refractory cases
Antiviral therapy:
- Zidovudine (AZT): Trials have shown mixed results
- Valganciclovir: Investigational
Symptomatic Management
- Spasticity: Baclofen, tizanidine, dantrolene
- Urinary dysfunction: Oxybutynin, catheterization
- Pain management: Gabapentin, pregabalin, antidepressants
- Physical therapy: Essential for maintaining mobility and preventing contractures
Prognosis
The disease follows a chronic progressive course over decades. Most patients require assistive devices (canes, walkers, wheelchairs) within 10-20 years of symptom onset.[^7] Life expectancy is generally normal, but quality of life can be significantly impacted by disability.
Relationship to Neurodegeneration
While HAM/TSP is primarily an infectious inflammatory disorder, it shares features with neurodegenerative diseases:
- Chronic [neuroinflammation](/mechanisms/microglia-neuroinflammation)
- Progressive axonal loss
- Spinal cord atrophy
- Motor neuron dysfunction
Research into HTLV-1 pathogenesis has provided insights into immune-mediated neurodegeneration relevant to conditions like [ALS](/therapeutics/amyotrophic-lateral-sclerosis-als-treatment) and [multiple sclerosis](/diseases/multiple-sclerosis).[@epidemiology]
Research Directions
Current research focuses on:
- Biomarkers for disease progression
- Novel immunomodulatory agents
- Understanding viral reservoirs
- Gene therapy approaches
- Neuroprotective strategies
See Also
- [Spinal Muscular Atrophy (SMA)](/diseases/spinal-muscular-atrophy)
- [Hereditary Spastic Paraplegia (HSP)](/diseases/hereditary-spastic-paraplegia)
- [Primary Lateral Sclerosis (PLS)](/diseases/primary-lateral-sclerosis)
- [Multiple Sclerosis (MS)](/diseases/multiple-sclerosis)
- [HTLV-1 and Neurodegeneration](/mechanisms/htlv-1-neurodegeneration)
- [Amyotrophic Lateral Sclerosis (ALS)](/therapeutics/amyotrophic-lateral-sclerosis-als-treatment)
External Links
- [NIH NINDS - HTLV-1 Associated Myelopathy](https://www.ninds.nih.gov/health-information/disorders/htlv-1-associated-myelopathy)
- [WHO - Human T-lymphotropic virus type I](https://www.who.int/news-room/fact-sheets/detail/human-t-lymphotropic-virus-type-1)
- [MedlinePlus - HTLV-1](https://medlineplus.gov/htlv1.html)
- [National Institutes of Health - HAM/TSP](https://pubmed.ncbi.nlm.nih.gov/2862418/)
Background
The study of Htlv 1 Associated Myelopathy (Ham) Tropical Spastic Paraparesis (Tsp) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Recent Research (2024-2026)
This section highlights recent publications relevant to this disease.
- [Expanding the neurological spectrum of HTLV-1 beyond HAM/TSP: a contemporary perspective.](https://pubmed.ncbi.nlm.nih.gov/41551295/) (2026 Mar) - Lancet regional health. Americas
- [Acanthamoeba myelopathy mimicking tropical spastic paraparesis in immunocompetent hosts: a case series.](https://pubmed.ncbi.nlm.nih.gov/41760966/) (2026 Feb 28) - Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
- [HTLV-1 Tax Reshapes the DNA-Binding Pattern of Transcription Factor IRF4 and Disrupts Host Gene Regulation.](https://pubmed.ncbi.nlm.nih.gov/41736671/) (2026 Feb 25) - Cancer science
- [Epidemiology of adult T-cell leukemia/lymphoma (ATL) in people living with HTLV-1: A 30-year study in Peru.](https://pubmed.ncbi.nlm.nih.gov/41729993/) (2026 Feb) - PLoS neglected tropical diseases
- [Assessment of Awareness and Knowledge Regarding Human T-Lymphotropic Virus Type 1 (HTLV-1) Among Healthcare Workers at Imam Khomeini Hospital Complex, Tehran, in 2023-2024, A Cross-Sectional Descriptive-Analytical Study.](https://pubmed.ncbi.nlm.nih.gov/41737423/) (2026 Feb) - Health science reports
References
[Unknown, Expanding the neurological spectrum of HTLV-1 beyond HAM/TSP: a contemporary perspective (n.d.)](https://pubmed.ncbi.nlm.nih.gov/41551295/)
[Unknown, Acanthamoeba myelopathy mimicking tropical spastic paraparesis in immunocompetent hosts: a case series (n.d.)](https://pubmed.ncbi.nlm.nih.gov/41760966/)
[Unknown, HTLV-1 Tax Reshapes the DNA-Binding Pattern of Transcription Factor IRF4 and Disrupts Host Gene Regulation (n.d.)](https://pubmed.ncbi.nlm.nih.gov/41736671/)
[Unknown, Epidemiology of adult T-cell leukemia/lymphoma (ATL) in people living with HTLV-1: A 30-year study in Peru (n.d.)](https://pubmed.ncbi.nlm.nih.gov/41729993/)
[Unknown, Assessment of Awareness and Knowledge Regarding Human T-Lymphotropic Virus Type 1 (HTLV-1) Among Healthcare Workers at Imam Khomeini Hospital Complex, Tehran, in 2023-2024, A Cross-Sectional Descriptive-Analytical Study (2023)](https://pubmed.ncbi.nlm.nih.gov/41737423/)